Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01936870
Study type Observational
Source Pfizer
Contact
Status Completed
Phase
Start date October 1, 2013
Completion date May 19, 2016

See also
  Status Clinical Trial Phase
Completed NCT00507169 - SVT-40776 in Patients Suffering From Overactive Bladder Syndrome Phase 2
Completed NCT02216214 - Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) Phase 4
Completed NCT02294396 - Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. Phase 4
Completed NCT03846895 - Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB) N/A
Completed NCT03903094 - A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
Terminated NCT04451382 - PTNS vs Botox of Refractory OAB
Terminated NCT04641975 - A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) Phase 3
Completed NCT00366002 - Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder Phase 4
Completed NCT02138747 - A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB) Phase 4
Completed NCT03602508 - Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Completed NCT03572231 - A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
Completed NCT05211193 - Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
Completed NCT04562090 - A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder Phase 4
Completed NCT00282932 - Detrol LA In Men With Overactive Bladder. Phase 4
Completed NCT01639794 - Vesitirimâ„¢ in Men Postmarketing Observational Study N/A
Completed NCT00742833 - A Phase II Study of KUC-7483 in Patients With Overactive Bladder Phase 2
Withdrawn NCT01317810 - A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication N/A